Publicaciones más relevantes

Destacamos algunas de las publicaciones más relevantes, de los últimos 5 años, del equipo impulsor del proyecto.

  1. Cortes J, Swain SM, Kudaba I, Hauschild M, Patel T, Grincuka E, Masuda N, McNally V, Ross G, Brewster M, Marier JF, Trinh MM, Garg A, Nijem I, visich J, Lum BL, Baselga J. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. Anticancer Drugs 2013; 24(10): 1084-92
  1. Oliveira M, Cortes J, Bellet M, Balmaña J, De Mattos-Arruda L, Gómez P, Muñoz-Couselo E, Ortega V, Pérez J, Saura C, Vidal M, Rubio I. T, Di Cosimo S. Management of the axilla in early Breast cancer patients in the genomic era. Ann Oncol 2013 May; 24(5): 1163-70
  1. Cordoba O, Llurba E, Saura C, Rubio I, Ferrer Q, Cortes J, Xercavins J. Multidisciplinary approach to breast cancer diagnosed during pregnancy: maternal and neonatal outcomes. Breast 2013; 22(4): 515-9
  1. Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Soltiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho Js. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 2012; 23(12): 2997-3006
  1. Torrejón D, Oliveira M, Cortes J, Sanchez-Olle G, Gómez P, Bellet M, Saura C, Peg V, Rovira A, Di Cosimo S. Implications of breast cancer phenotype for patients with leptomeningeal carcinomatosis. Breast 2013; 22(1): 19-23
  1. Somlo G, Atzori F, Strauss LC, Geese W, Specht JM, Gradishar WJ, Rybicki A, Sy O, Vahdat LT, Cortes J. Dasatinib Plus Capecitabine for Advanced Breast Cancer: Safety and Preliminary Efficacy in Phase I Study CA180004. Clin Cancer Res 2013 Apr 1; 19(7): 1884-93
  1. Swain SM, Ewer MS, Cortes J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G, Baselga J. Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients with HER2-Positive Metastatic Breast Cancer in Cleopatra: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. Oncologist 2013; 18(3): 257-64
  1. Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortes JDelmar PR, Scherer SJ. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cáncer. Br J Cancer 2013 Mar 19; 108(5): 1052-60
  1. Serra, V, P. J. Eichhorn, C. García-García, Y. H Ibrahim, L. Prudkin, G. Sánchez, O. Rodríguez, P. Antón, J. L Parra, S. Marlow, M. Scaltriti, Perez Garcia J, A. Prat, J. Arribas, W. C Hahn, S. Y Kim and J. Baselga. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, 2013. 123(6): p. 2551-2563
  1. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsa Y-F, Ratnayake J, McNally V, Ross G, Cortes J. Pertuzumab Plus Trastuzumab in Combination With Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients With HER2-Positive Early Breast Cancer: A Randomized Phase II Cardiac Safety Study (TRYPHAENA). Ann of Oncol 2013 ; 24(9): 2278-84
  1. De Mattos-Arruda L, Cortes J, L. Santarpia, A. Vivancos, J. Tabernero, Jorge S. Reis-Filho, J. Seoane. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 2013 Jul; 10(7): 377-89
  1. Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomized, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013 May; 14(6): 461-71
  1. Torrejon D, Cortes J, Serico D, Di Cosimo S. In reply to the article by F. Vasseur et al. : Ki67 in young patients with breast cancer. GynecolObstetFertil 2013; 41 (1): 16-9
  1. Martino-Echarri, E; Fernandez-Rodriguez, R; Rodríguez-Baena, FJ; Barrientos-Durán, A; Torres-Collado, AX; Plaza-Calonge, MD; Amador-Cubero, S; Cortes J; Reynolds, LE.; Hodivala-Dilke, K; Rodriguez-Manzaneque, JC. Contribution of ADAMTS1 as a tumor suppressor gene in human breat carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on Nidogen-1 and Nidogen-2. Int J Cancer 2013; 133(10): 2315-24
  1. Andre, F. Bachelot, M. Campone, F. Dalenc, Perez Garcia J, S. A Hurvitz, N. C Turner, H. Rugo, J. W Smith, S. Deudon, M. M Shi, Y. Zhang, A. Kay, D. Graus Porta, A. Yovine and J. Baselga. Targeting FGFR WithDovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer. Clin Cancer Res, 2013. 19(13): p. 3693-3702
  1. González-Sánchez E; J Martin-Caballero J; Flores JM, Hernandez-Losa J; Ma Angeles Montero; Cortes J; Mares R; Barbacid M; Recio JA. Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas. Plos One 2013 Jun 25; 8(6): e66933
  1. Miles DW, Diéras V, Cortes J, Duenne A-A, Yi J, O’Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patiens. Ann Oncol 2013; 24(11): 2773-80
  1. Cortes J, Baselga J, Im YH, Im SA, Pivot X, Ross G, Clark E, Knott A, Swain SM. Health-related quality of life assessment in CLEOPATRA, a Phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol 2013; 24(10): 2630-5
  1. Haba-Rodríguez J de L, González A, Cortes J, Rodríguez-Lescure A, Sánchez A, Pulido G, Cortijo A, Guirado M, Torrejón D, Alba E. Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens. Anticancer Drugs 2013, 24(9): 975-979
  1. Perez García J, Muñoz-Couselo E, Cortes J. The effect of biology in the treatment of small breast tumours. American Society of Clinical Oncology Educational Book/ ASCO. American Society of clinical Oncology 2013: 2013: 25-31.
  1. De Mattos-Arruda L, Cortes J. Use of pertuzumab for treatment of HER2-positive metastatic breast cancer. AdvTher 2013,30 (7): 645-658
  1. Perez Garcia J, Cortes J. Adjuvant bevacizumab: positive data from a negative trial. Lancet Oncol 2013; 14(10): 910-1.
  1. Curigliano G, Pivo X, Cortes J, Elias A, Cesari R, Khorsravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast 2013; 22(5): 650-6
  1. Garg A, Li J, Clark E, Knott A, Carrothers TJ, Marier JF, Cortes J, Brewster M, Visich J, Lum B. Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absense of effect on QTc prolongation and other ECG parameters. Cancer Chemother Pharmacol 2013, 72(5): 1133-41.
  1. Di cosimo S, De Mattos-Arruda L, Isabel R, Cortes J. Re: Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions. J Natl Cancer Inst 2013, Dec 18; 105(24): 1912
  1. Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Palmeg HG, Dawood S, Rodon J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortes J. GenomicAnalyses across Six Cancer types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep 2013, 3: 3544
  1. Llombart Cussac A, de la Haba Rodríguez J, Ruiz Simón A, Alvarez Lopez I, Cortes J. SEOM clinical guidelines for the management of metastatic breast cancer. Clin Transl Oncol 2013 Dec; 15812): 1004-10.
  1. Dienstmann R, Rodon J, Prat A, Perez García J, Adamo B, Felip E, Cortes J, Lafrate AJ, TaberneroJ. Genomicaberrations in the FGRF pathway: opportunities for targeted therapies in solidtumors. Ann Oncol 2014, 25(3): 552-63.
  1. Perez A, Cortes J, Gonzalez-Angulo A. M, Barlett, J. M. S. HER2 Testing: Current status and future directions. Cancer Treat Rev 2014, 40(2): 276-84.
  1. De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA,Weiglet B, Berger MF, Seoane J, Reis-Filho JS. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of masively parallel sequencing. Mol Oncol 2014 Feb; 8(1): 150-5
  1. Cortes J, Calvo E, Vivancos A, Perez-Garcia J, Recio JA, Seoane. J. New Approach to Cancer Therapy Based on a Molecularly Defined Cancer Classification. CA Cancer J Clin 2014 Jan; 64(1): 70-4
  1. Muss H, Cortes J, Vahdat LT, CardosoF, Twelves C, Wanders J, Dutcus CE, Yang J, Seegobin S, O’Shaughnessy J. Eribulin Monotherapy in Patients 70 Years and Older with Metastatic Breast Cancer. Oncologist 2014; 19: 1-10
  1. Rubio I, Landolfi S, Molla M, Cortes J, Xercavins J. Breast conservative surgery followed by radiofrequency ablation of margins decrease the need for a second surgery for close or positive margins. Clin Breast Cancer 2014 Oct; 14(5): 346-51
  1. Cortes J, Curigliano G, Diéras V. Expert perspectives on biosimilar monoclonal antibodies in breast cancer. Breast Cancer Res Treat 2014 Apr; 144(2): 233-9
  1. Baselga J, Manikhas A, Cortes J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol 2014 Mar; 25(3): 592-8
  1. Dawood S, Lei X, Dent R, Gupta S, Sirohi B, Cortes J, Cristofanilli M, Buchholz T, Gonzalez-Angulo AM. Survival of women with inflammatory breast cancer: A large population based study. Ann Oncol 2014 Jun; 25(6): 1143-51
  1. Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, Cortes J. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol 2014 Jun; 25(6): 1116-21
  1. Marco V, Muntal T, García-Hernandez F, Cortes J, Gonzalez B, Rubio IT. Changes in Breast Cancer Reports after Pathology Second Opinion. Breast J 2014; 20(3): 295-301
  1. Schneeweiss A, Chia S, Hegg R, Tausch C, Deb R, Ratnayake J, McNally V, Ross G, Kiermaier A, Cortes J. Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. Breast Cancer Res 2014; 16(4): R73
  1. De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS. Capturing Intra-Tumor Genetic Heterogeneity by De Novo Mutation Profiling of Circulating Cell-Free Tumor DNA: A Proof-op-Principle. Ann Oncol 2014; Sep; 25(9): 1729-35
  1. Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, Smith I, Thomssen C, Srock S, Sampayo M, Cortes J. A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial. Breast 2014; Oct; 23(5): 656-62
  1. Prat A, Carey LA, Adamo B, vidal M, Tabernero J, Cortes J, Parker JS, Perou CM, Baselga J. Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer. J Natl Cancer Inst 2014; 106(8): dju152
  1. Garg A, Quartino A, Li J, Jin J, Wada DR, Li H, Cortes J, McNally V, Ross G, Visich J, Lum B. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors. Cancer Chemother Pharmacol 2014 Oct; 74(4): 819-29
  1. Ramon y Cajal S, De Mattos-Arruda L, Sonenberg N, Cortes J, Peg V. The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets. Clin Transl Oncol 2014 Nov; 16(11): 937-41)
  1. Von Minckwitz G, Puglisi F, Cortes J, Vrdojak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, De Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-lable, randomised phase 3 trial. Lancet Oncol 2014 Oct; 15(11): 1269-78
  1. Parra- Palau Jl, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, Zacarias-Fluck M, Pedersen K, Pandiella A, Nuciforo P, Serra V, Cortes J, Baselga J, Perou CM, Prat A, Rubio IT, Arribas J. Effect on ph95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. J Natl Cancer Inst 2014 Sep 24; 106(11)
  1. Seguí MA, Crespo C, Cortes J, Lluch A, Brosa M, Becerra V, Chiavenna SM, Gracia A. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective. Expert Rev Pharmacoecon Outcomes Res 2014 Dec; 14(6): 889-99.
  1. Saura C, García-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, Cortés J, Kiger C, Germa C, Wang K, Martin M, Baselga J, Kim SB. Safety and Efficacy of Neratinib in combination with Capecitabine in patients with metastatic human epidermal growth factor recpetor 2-positive breast cancer. J Clin Oncol 2014 Nov 10; 32(32): 3626-33
  1. Baselga J, Cortes J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM. Biomarker Analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 2014 Nov 20; 32(33): 3753-61
  1. Esteve-Puig R, Gil R, González-Sánchez E, Bech-Serra JJ, Gureso J, Hernández-Losa J, Moliné T, Canals F, Ferrer B, Cortes J, Bastian B, Ramon y Cajal S, Martín-Caballero J, Flores JM, Vivancos A, García-Patos V, Recio JA. A mouse model uncovers LKB1 as an UVB-induced DNA damage seson mediating CDKN1A (p21WAF1/CIP1) degradation. Plos Genet 2014 Oct 16; 10(10): e1004721
  1. Pérez García J, Muñoz-Couselo E, Cortes J , Scaltriti M. Therapeutic Antibodies in Breast Cancer. Semin Oncol 2014; 41: 576-588.
  1. Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 2014 Dec; 148(3): 553-61
  1. Jackisch C, Scappaticci FA, Heinzmann D, Bisordi F, Schreitmüller T, von Minckwitz G, Cortes J. Neoadjuvant breast cancer treatment as a senstivie setting for trastuzumab biosimilar development and extrapolation. Future Oncol 2015 Jan; 11(1): 61-71.
  1. Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis CE, Eidtmann H, Arribas J, Cortes J, De Azambuja E, Piccart M, Baselga J. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res. 2015 Feb 1; 21(3): 569-76
  1. Andre F, Cortes J. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat 2015 Feb; 150(1): 1-8.
  1. Spreafico A, Delord JP, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, Bedard PL, Akimov M, Lu H, Pain S, Kaag A, Siu LL, Cortes J. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer 2015 2015 Feb 17; 112(4): 650-9
  1. Bedard, P. L., J. Tabernero, F. Janku, Z. A Wainberg, L. Paz-Ares, J. Vansteenkiste, E. Van Cutsem, Perez Garcia J, A. Stathis, C. D Britten, N. T. Le, K. Carter, D. Demanse, D. Csonka, M. Peters, A. Zubel, H. Nauwelaerts and C. Sessa. A phase lb dose escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumours. Clin Cancer Res, 2015. 21 (4): p. 730-738
  1. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Scheneeweiss A, Heeson S, Clark E, Ross G,Benyunes MC, Cortes J. Pertuzumab, Trastuzumab, Docetaxel in HER2-Positive Metastatic Breast Cancer. New Eng J Med 2015 Feb 19; 372(8): 724-34
  1. Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated with Antracycline and a Taxane. J Clin Oncol 2015 Feb 20; 33(6): 594-601
  1. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Parazentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies. Nat Genet 2015 Mar; 47(3): 250-6
  1. Vidal M, Peg V, Galvan P, Cortes J, Ramon y Cajal S, Rubio I, Prat A. Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast. Mol Oncol 2015 Jun; 9(6): 1081-90
  1. Twelves C, Jove M, Cortes J. Recognising the place of trials with treatment of physician’s choice (tpc) as the control arm. J Clin Oncol 2015 Apr 10; 33(11): 1300-1]
  1. Arana E, Kovacs FM, Royuela A, Asenjo B, Pérez-Ramírez U, Zamora J; Spanish Back Pain Research Network Task Force for the improvement of inter-disciplinary management of spinal metastasis Holgado E. Radiother Oncol 2015 Apr; 115(1): 135-40
  1. Dawood S, Haaland B, Albaracin C, Gupta S, Cortes J, Sim YY, Dent RA. Is the proportion of patients diagnosed with synchronous stage IV Breast Cancer Who survive more thant two years increasing over time? Oncology 2015; 89(2): 79-87
  1. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone recpetor-positive breast cancer. Sci Transl Med 2015 Apr 15: 7(283): 283ra51
  1. Moya-Horno I, Cortes J. The expanding role of pertuzumab in the treatment of HER2- Breast Cancer (Dove med Press) 2015 may 21; 7: 125-32
  1. Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal A, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortes J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS One 2015; 10(6): e0129876
  1. Brahmer, M. D. , Karen L. Reckamp, M. D. , Paul Baas, M. D. , Lucio Crinò, M. D. , Wilfried E. E. Eberhardt, M. D. , Elena Poddubskaya, M. D. , Scott Antonia, M. D. , Ph. D. , Adam Pluzanski, M. D. , Ph. D. , Everett E. Vokes, M. D. , Holgado E, M. D. , Ph. D., David Waterhouse, M. D. , Neal Ready, M. D. , Justin Gainor, M. D. , Osvaldo Arén Frontera, M. D. , Libor Havel, M. D. , Martin Steins, M. D. , Marina C. Garassino, M. D. , Joachim G. Aerts, M. D. , Manuel Domine, M. D. , Luis Paz-Ares, M. D. , Martin Reck, M. D. , Christine Baudelet, Ph. D. , Christopher T. Harbison, Ph. D. , Brian Lestini, M. D. , Ph. D. , and David R. Spigel, M. D. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine 2015 Jul 9; 373(2): 123-35
  1. Hossein Borghaei, D. O., Luis Paz-Ares, M. D., Leora Horn, M. D., David R. Spigel, M. D., Martin Steins, M. D., Ph. D., Neal E. Ready, M. D., Ph. D., Laura Q. Chow, M. D , Everett E. Vokes, M. D., Enriqueta Felip, M. D., Holgado E, M. D , Fabrice Barlesi, M. D., Ph. D , Martin Kohlhäufl, M. D., Ph. D., Oscar Arrieta, M. D., Marco An gelo Burgio, M. D., JérômeFayette, M. D., Ph. D., Hervé Lena, M. D., Elena Poddubskaya, M. D., David E. Gerber, M. D., Scott N. Gettinger, M. D., Charles M. Rudin, M. D., Ph. D., NaiyerRizvi, M. D., Lucio Crinò, M. D., George R. Blumenschein, Jr., M. D., Scott J. Antonia, M. D., Ph. D., CécileDorange, M. S., Christopher T. Harbison, Ph. D., Friedrich Graf Finckenstein, M. D., and Julie R. Brahmer, M. D. Nivolumab versus Docetaxel in Advanced Nonsquamous-Cell Non-Small-Cell LungCancer. The New England Journal of Medicine 2015 Oct 22; 373(17): 1627-39
  1. González-Martín A, Alba E, Ciruelos E, Cortes J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M. Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. Curr Cancer Drug Tragets 2016; 16(5): 415-28
  1. Morris GJ, Dawood S, Cortes J, Ward JH, Vaklavas C, Forero A, Ward S, Toppmeyer D. Sub-centimeter HER2-Positive Breast Cancer: How Small is too small to treat? Semin Oncol 2015 Agu: 42(4): e67-79
  1. Muñoz-Couselo E, García JS, Pérez García J, Cebrián VO, Cortes J. Recent Advances in the treatment of melanoma with BRAF and MEK inhibitors. Ann Transl med 2015 Sep; 3(15)207
  1. Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, Muñoz-Couselo E, Manzano JL, Cortes J, Berros JP, Drozdowskyj A, Sanmamed M, Gonzalez A, Alvarez C, Viteri S, Karachaliou N, Martin Algarra S, Bertran-Alamillo J, Jordana-Ariza N, Rosell R. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res 2015 Dec; 25(6): 486-95
  1. De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez García J, Masci G, Corsi F, Cortes J, Seoane J, Calin GA, Santarpia L. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget Nov 10; 6(35): 37269-8
  1. Pérez EA, Wada A, O’Shaugnessy J, Rugo H, Twelves C, Im S-A, Gómez-Pardo P, Schwartzberg L, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn J-S, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J. Etirinotecan pegol (NKTR-102) versus treatment of physician’s choice in women with advanced breast cancer previously treated with and anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-lable, multicentre, phase 3 trial. Lancet Oncol 2015 Nov; 16(15): 1556-68
  1. Cortes J. MD, on the CELOPATRA Trial. Oncology (Williston Park) 2015 Oct; 29(10): 718
  1. Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, McCutcheon S, Kaufman PA, Forsythe A, Velikova G. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-lable randomized phase 3 trial. Breast Cancer Res Treat 2015 Dec; 154(3): 509-20
  1. De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Tower R, Vivancos A, Peg V, Cajal SR, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015 Nov 10; 6: 8839
  1. Cortes J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espié M, Kim SB, Scheneeweiss A, Sohn JH, Nabholtz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H. Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastatses after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol 2015 Dec; 16(16): 1700-10
  1. Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O’Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcitystudy): study protocol for a randomized controlled trial. Trials 2015 Dec 16; 16(1): 575
  1. Holgado E, Perez Garcia J, Wren A, Cortes J, Gomez-Pinillos A. Influencing cancer treatment. Lancet Oncol 2015 Dec 16(16): 1591-3
  1. Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Pérez García J, Arribas J, Cortes J, Scaltriti M. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol Oncol 2016 Jan; 10(1): 138-47
  1. Vivancos A, Caratú G, Matito J, Muñoz E, Ferrer B, Hernández-Losa J, Bodet D, Pérez-Alea M, Cortes J, Garcia-Patos V, Recio JA. Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations. Pigment Cell Melanoma Res 2016 Mar: 29(2): 247-53
  1. Arpino G, Marmé F, Cortes J, Ricevuto E, Leonard R, Llombart-Cussac A. Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts. Crit Rev Oncol Hematol 2016 Mar; 99: 81-90. Review
  1. López-Miranda E, Cortes J. Etirnotecan Pegol for the Treatmen of Breast Cancer. Expert Opin Pharmaco 2016 Feb. 17(5): 727-34
  1. Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D,Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel. Ann Oncol 2016 Mar; 27(3): 379-90
  1. Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman A, Rodriguez O, Grueso J, Bellet M, Cortes J, Elliott R, Pancholi S, Baselga J, Dowselt M, Martin LA, Turner NC, Serra V. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Recpetor-Positive Breast Cancer. Cancer Res 2016 Oct 1; 76(19): 5907
  1. Pérez-Alea M, Vivancos A, Caratú G, Matito J, Ferrer B, Hernandez-Losa J, Cortes J, Muñoz E, Garcia-Patos V, Recio JA. Gentetic profile of GNAQ-mutated blue melanocytic neoplasm reveals mutations in genes linked to genomic instability and the PI3K pathway. Oncotarget 2016, May 10; 7(19): 28086-95
  1. Liu MC, Cortes J, O’Shaughnessy J. Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast càncer with brain metàstasis. Cancer Metastasis Rev 2016 Jun; 35(2): 323-32
  1. Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor C, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell A, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner J, Mammen JM, McGinness M, Klemp JR, Amin A, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M. Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohorts. Clin Cancer Res 2017, Feb 1; 23(3)649-657
  1. Goldman JW, Crino L, Vokes EE, Holgado E, Reckamp K, Pluzanski A, Spigel D, Kohlhaeufl M, Garassino M, Chow LQ, Gettinger S, Gerber DE, Havel L, Ramalingam SS, Dy GK, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Lopes G. 36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy. JThorac Oncol 2016 Oct; 11(10S): S238-S239
  1. Diaz-Botero S, Espinosa-Bravo M, Gonçalves VR, Esgueva-Colmenarejo A, Peg V, Perez J, Cortes J, Rubio IT. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response. Ann Surg Oncol. 2016 Nov 23; (12): 3831-3837
  1. Awada A, Cortes J, Martín M, Aftimos P, Oliveira M, López-Tarruella S, Espie M, Lardelli P, Extremera S, Fernández-García EM, Delaloge S. Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. Clin Breast Cancer 2016 Oct; 16(5): 364-371
  1. Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I, Yardley DA. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer 2016 Jun 3; 16(1): 352
  1. Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, Song J, Dutcus CE, Kaufman PA. Subgroup Analyses formaPhase 3, Open-Label, Randomized Sutdy of Eribulin Mesylate Versus Capectiabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer: Basic and Clinical Research 2016: 10
  1. Cortes J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, O’Shaughnessy J. Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. Springerplus 2016 Jul 8; 5(1): 1033
  1. Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget 2016 Aug 30; 7(35): 56295-56308
  1. Quintela-Fandino M, Lluch A, Manso LM, Calvo I, Cortes J, García-Saenz JA, Gil JM, Martinez-Jañez N, González-Martín A, Adrover E, De Andres R, Viñas G, Llombart Cussac A, Alba E, Guerra J, Bermejo B, Zamora E, Moreno-Anton F, Pernas-Simon S, Carrato A, Lopez A, Escudero MJ, Campo R, Carrasco EM, Palacios J, Mulero F, Colomer R. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: a window-of-opportunity randomized trial. Clin Cancer Res 2017 Mar 15; 23(6): 1432-1441
  1. Morancho B, Zacarías-Fluck M, Esgueva A, Di Cosimo S, Prat A, Cortes J, Arribas J, Rubio IT. Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. Oncotarget 2016 Oct 18; 7(42): 67956-67965
  1. Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, O’Connor MJ, Gray J, Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell 2016 Sep 22; 167(1): 260-274
  1. Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol 2016 Nov; 27(11): 2046-2052
  1. González A, Lluch A, Aba E, Albanell J, Antón A, Álvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortes J, de la Haba J, López-Vega JM, Martínez E, Muñoz M, Peláez I, Redondo A, Rodríguez A, Rodríguez CA, Ruíz Un, Lombart A. A definition for aggressive desease in patients with HER-2 negative metastasic breast cáncer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). Clin Oncol Transl 2017 May; 19(5): 616-624
  1. De Mattos-Arruda, Sher R, Reis-Filho JS, Cortes J. Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol 2016 Sep; 13(9): 566-79
  1. Musolino A, Campone M, Neven P, Denduluri N, Barrios CH, Cortes J, Blackwell K, Soliman H, Kahan Z, Bonnefoi H, Squires m, Zhang Y, Deudon S, Shi MM, André F. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res 2017 Feb 10; 19(1): 18
  1. Cejalvo JM, Martínez de Dueñas E, Galvan P, García-Recio S, Burgués Gasión O, Paré L, Antolin S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano A, Muñoz M, Nuciforo P, Vidal M, Pérez RM, Chacón López-Muñiz JI, Caballero R, Peg V, Carrasco E, Rojo F, Perou CM, Cortes J, Adamo V, Albanell J, Gomis RR, Lluch A, Prat A. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res 2017 May 1; 77(9): 2213-2221
  1. Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA. Critically short telomeres and toxicity of chemotherapy in early breast cáncer. Oncotarget 2017 Mar 28; 8(13): 21472-21482
  1. Nogova,, L. V Sequist, Perez Garcia J, F. Andre, J. P Delord, M. Hidalgo, J. H. M Schellens, P. A Cassier, D. R Camidge, M.  Schuler, U. Vaishampayan, H. Burris, G. G Tian, M. Campone, Z. A Wainberg, W-T Lim, P. LoRusso, G. I Shapiro, K. Parker, X. Chen, S. Choudhury, F. Ringeisen, D. Graus-Porta, D. Porter, R. Isaacs, R. Buettner and J. Wolf. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. J Clin Oncol 2017. 35 (2): p. 157-165
  1. Muñoz-Couselo, E. , E. Zamora Adelantado, C. Ortiz, J. Soberino Garcia, and Perez Garcia J. NRASmutant melanoma: current challenges and future prospect. Onco Targets Ther 2017. 10: p. 3941-47
  1. Twelves C, Cortes J, O’Shaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecanpegol versus treatment of physician’s choice: Results from the randomised phase III BEACON trial. Eur J Cancer 2017 May; 76: 205-215
  1. Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2017 Jun; 163(3): 535-544
  1. Peg V, Sansano I, Vieites B, Bernet L, Cano R, Córdoba A, Sancho M, Martín MD, Vilardell F, Cazorla A, Espinosa-Bravo M, Pérez-García J, Cortes J, Rubio IT, Ramón Y Cajal S. Role of total tumour load of sentinel lymph node on survival in early breast cancer patients. Breast 2017 Jun; 33: 8-13
  1. Llombart-Cussac A, Cortes J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A. ; HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol 2017 Apr; 18(4): 545-554
  1. Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, Baselga J. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol 2017 Apr 1; 28(4): 761-768
  1. Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, PlàMJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortes J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA; Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene 2017 May 11; 36(19): 2737-2749.
  1. Cardoso F, Harbeck N, Barrios CH, Bergh J, Cortes J, El Saghir N, Francis PA, Hudis CA, Ohno S, Partridge AH, Sledge GW, Smith IE, Gelmon KA. Research needs in breast cancer. Ann Oncol 2017 Feb 1; 28(2): 208-217
  1. Leora Horn, David R. Spigel, Everett E. Vokes, Holgado E, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz-Ares, Adam Pluzanski, Karen L. Reckamp, Marco A. Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlesi, Scott Antonia, Oscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood-Chirchir, Diane Healey, Julie Brahmer, and Wilfried E. E. Eberhardt. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017 Dec 10; 35(35): 3924-3933
  1. Calvo E, Moreno V, Flynn M, Holgado E, Olmedo ME, Lopez Criado MP, Kahatt C, Lopez-Vilariño JA, Siguero M,Fernandez-Teruel C, Cullell-Young M, Soto Matos-Pita A, Forster M. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. Ann Onc 2017 Oct 1; 28(10): 2559-2566
  1. Maetens M, Brown D, Irrthum A,Aftimos P, Viale G, Loibl S,Labes J, Campbell PJ, Thompson A, Cortes J, Seiler S, Vinnicombe S, Oliveira M, Rothé F, Bareche Y, Fumagalli D, Zardavas D, Desmedt C, Piccart M, Loi S,Sotiriou C. The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group. NPJ Breast Cancer (2017) Jun 29; 3: 23
  1. Pérez-Alea M, McGrail K, Sánchez-Redondo S, Ferrer B, Fournet G, Cortes J, Muñoz E, Hernandez-Losa J, Tenbaum S, Martin G, Costello R, Ceylan I, Garcia-Patos V, Recio JA. ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment. Oncogene 2017 Oct 12; 36(41): 5695-5708
  1. Cortes J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A ,Moreno- Aispitia A , Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O’Shaughnessy J. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat 2017 Jun 13. 2017 Nov; 166(1): 327-328
  1. Rugo HS, Trédan O, Ro J, Morales SM, Campone M, Musolino A, Afonso N, Ferreira M, Park KH, Cortes J, Tan AR, Blum JL, Eaton L, Gause CK, Wang Z, Im E, Mauro DJ, Jones MB, Denker A, Baselga J. A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. Breast Cancer Res Treat 2017 Oct; 165(3): 601-609.
  1. Baselga J, Im SA, Iwata H, Cortes J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Jul; 18(7): 904-916
  1. Dickler MN, Tolaney SM, Rugo HS, Cortes J, Diéras V, Patt D, Wildiers H, Hudis CA, O’Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin CancerRes 2017 Sep 1; 23(17): 5218-5224
  1. Nuciforo P, Pascual T, Cortes J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P,Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P,Prat A, Holgado E. A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol 2017 Oct 12 (en prensa)
  1. Baselga J, Coleman RE, Cortes J, Janni W. Advances in the Management of HER2-Positive Early Breast Cancer. Crit Rev Oncol Hematol 2017 Nov; 119: 113-122
  1. Vega JF, Ramos J, Cruz VL, Vicente-Alique E, Sánchez-Sánchez E, Sánchez-Fernández A, Wang Y, Hu P, Cortes J, Martínez-Salazar J. Molecular and hydrodynamic properties of human epidermal growth factor receptor HER2 extracellular domain and its homodimer: Experiments and multi-scale simulations. BiochimBiophys Acta – General Subjects 2017 Sep; 1861(9): 2406-2416
  1. Cortes J, Im S, Holgado E, Perez Garcia J, Schmid P, Chavez-MacGregor M. The next era of treatment for HR+/HER2– advanced breast cancer: clinical trials of triplet combinations. Cancer Treat Rev 2017 Dec; 61: 53-60
  1. De Melo Gagliato D, Cortes J, Curigliano G, Loi S, Denkert C, Perez Garcia J><</strong, Holgado E. Tumor-Infiltrating Lymphocytes in Breast Cancer and Implications for Clinical Practice. BiochimBiophys Acta- Reviews on Cancer 2017 Dec; 1868(2): 527-537
  1. Perez Garcia J, Muñoz E,Soberino J, Racca F, Cortes J. Targeting FGFR pathway in Breast Cancer. Breast 2018 Feb; 37: 126-133
  1. Méndez-Pertuz M, Martínez P, Blanco-Aparicio C, Gómez-Casero E, Belen García A, Martínez-Torrecuadrada J, Palafox M, Cortés J, Serra V, Pastor J, Blasco MA. . Modulation of telomere protection by the PI3K/AKT pathway. Nat Commun 2017 Nov 2; 8(1): 1278
  1. Perez García J, Cortés J. Breast cancer in 2017: Spurring science, marking progress, and influencing history. Nat Rev Clin Oncol 2018 Feb; 15(2): 79-80
  1. SchneeweissA, ChiaS, HickishT, HarveyV,EniuA, Waldron-LynchM, Eng-WongJ, KirkS, Cortés J. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 2018 Jan; 89: 27-35
  1. Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García M. A, Cortés J, Rojo F, Martín M, Palacios-Calvo J. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol 2017 Dec 22. (en prensa)
  1. Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy MJ, Von Moos R, Cortés J, Vidal MJ, Hennessy B, Walshe J, Amillano Parraga K, Ribi K, Bernhard J, Morales SM, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan MM, Jerusalem G. A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Ann Oncol 2017 Dec 8. (en prensa)
  1. Başaran GA, Twelves C, Diéras V, Cortés J, Awada A. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2017 Dec 6; 63: 144-155.
  1. Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Invest New Drugs 2018 Jan 19. (en prensa)
  1. Parker J, Carey C, Schaper C, Traina T, Cortes J, Tudor L,PetersonA,Uppal H. Development of a Novel Binary Genomic Signature to Predict Response to Enzalutamide in Patients with Triple-Negative Breast Cancer. J Clin Oncol 2018 (en prensa)
  1. Cortes J, Perez Garcia J, Levy C, Gómez Pardo P, Bourgeois H, Spazzapan S, Martínez-Jañez N, Chao T, Espié M, Nabholtz JM,Gonzàlez Farré X, Beliakouski V, Román García J, Holgado E, Campone M. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer. Ann Oncol 2018 (en prensa)
  1. Pernas S, Martin M, A. Kaufman P, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, O. Ademuyiwa F, Weilbaecher K,Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia P, Wach A, Barker D, Fung S, Romagnoli B, Cortes J. The CXCR4 antagonist, balixafortide, plus eribulin in HER2-negative metastatic breast cancer: a Phase I, open-label, single-arm trial. Lancet Oncol (en prensa)
  1. Gonzalez-Cao M, Mayo de las Casas C, Jordana Ariza N,. Manzano JL, Molina-Vila M, Soriano V, Puertolas T, Balada A, Soria A, Majem M, Montagut C, Muñoz E, Rodríguez D, Perez, E, Garcia A, Cortes J, Drozdowskyj A, Karachaliou N, Rosell R; Early evolution of BRAFV600 status in the blood of melanoma patients correlate with clinical outcome and identifies patients refractory to therapy. Melanoma Res 2018 (en prensa)
  1. Rugo HS, Cortes J , Awada A, O’Shaughnessey Joyce , Twelves CJ , ImS, Hannah A , Lu L, Sy S , Caygill K, Zajchowski D, W. Davis D, Tagliaferri M , Perez E. Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecanpegol. Clin Cancer Res 2018 (en prensa)
  1. Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. Nat Cell Biol 2018 Feb; 20(2): 211-221
  1. Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O’Shaughnessy J,Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-NegativeBreast Cancer. J Clin Oncol. 2018 (en prensa)
  1. Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, ArénFrontera O, Gettinger S, Holgado E,Spigel D, Waterhouse D, Domine M, Garassino M, Chow LQM, Blumenschein G Jr, Barlesi F, Coudert B, Gainor J, Arrieta O, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Crinò L. Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 2018 Feb 2. (en prensa)
  1. Rugo HS, Cortes J. The new world of biosimilars in oncology: translation of data to the clinic. Eur J Cancer 2018 (en prensa)
  1. Ignatiadis M, Vandeneynden G, Salgado R, FornilMi, Bareche Y, Desmedt C, Venet D, Holgado E, McNally V, Kiermaier A, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C. Tumor infiltrating lymphocytes before and after dual HER2 blockade plus chemotherapy in HER2-amplified early breast cancer: A TRYPHAENA translational J Natl Cancer Inst 2018 (en prensa)
  1. Cortes J, Pérez-García J, Whiting S, Wan Y, Solem C, TaMi, Margunato-Debay S, Ko A, Fandi A, Botteman M. Quality-Adjusted Survival With nab-Paclitaxel vs Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis. Clin Breast Can 2018 (en prensa)
  2. De Mattos-Arruda L, K. Y. Ng C, Piscuoglio S, Gonzalez-Cao M, S. Lim R, R. De Filippo M, Fusco N, M. Schultheis A, OrtizC, Viteri S, Arias A, S. Macedo G, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon y Cajal S, Tresserra Casas F, Weigelt B, Cortes J, Seoane J, S. Reis-FilhO J. Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget 2018 (en prensa)